Eisai Bolsters Oncology Pipeline by Acquiring Rights to Huya’s Cancer Drug
By Jasmine Kalsi & Taskin Ahmed
Pharma Deals Review: Vol 2016 Issue 2 (Table of Contents)
Published: 25 Feb-2016
DOI: 10.3833/pdr.v2016.i2.2143 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
As part of its strategy to focus on oncology, Eisai has acquired an exclusive license agreement for HBI-8000, a histone deacetylase (HDAC) inhibitor from Huya Bioscience for US$280 M, which covers eight Asian countries including Japan...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS